Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

The primary objective of this 2-part phase 1/2 study was to determine the maximum-tolerated dose (MTD) of the potent and selective Aurora B kinase inhibitor barasertib (AZD1152) in patients with newly diagnosed or relapsed acute myeloid leukemia (AML). Part A determined the MTD of barasertib adminis...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Löwenberg, Bob, Muus, Petra, Ossenkoppele, Gert, Rousselot, Philippe, Cahn, Jean-Yves, Ifrah, Norbert, Martinelli, Giovanni, Amadori, Sergio, Berman, Ellin, Sonneveld, Pieter, Jongen-Lavrencic, Mojca, Rigaudeau, Sophie, Stockman, Paul, Goudie, Alison, Faderl, Stefan, Jabbour, Elias, Kantarjian, Hagop
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2011
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4186639/
https://ncbi.nlm.nih.gov/pubmed/21976672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-07-366930
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia